Delving into the Latest Updates on Betanin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

STAT3

Action

inhibitors

Mechanism

STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Acute Kidney InjuryParkinson Disease

Inactive Indication-

Originator Organization

University of Tabuk

Active Organization

Warszawski Uniwersytet Medyczny

University of Tabuk

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Natural phytoconstituents such as betanin and curcumin have attracted interest for their significant antioxidant and anti-inflammatory properties. Their therapeutic efficacy is notably constrained by inadequate bioavailability and reduced skin permeability. The current study developed an ethosome-based gel system for the delivery of betanin and curcumin, with the objective of improving transdermal penetration and providing sustained anti-inflammatory effects. Ethosomes were formulated by cold method and optimised for physicochemical characteristics including particle size, zeta potential and entrapment efficiency. The optimised formulation exhibited a mean particle size of 202.8 nm, a zeta potential of -56.4 mV and high entrapment efficiencies of 80% for betanin and 85% for curcumin. The characterisation using SEM and FT-IR confirmed the successful encapsulation and structural integrity of the ethosomes. The ethosomal gel demonstrated an optimal pH of 6.5, pseudoplastic viscosity and superior spreadability, making it appropriate for topical use. In vitro diffusion studies demonstrated a sustained release profile lasting 8 h. Skin irritation tests confirmed its biocompatibility. The in vivo anti-inflammatory efficacy was assessed in rats by utilising carrageenan model of inflammation, results showed that ethosomal gel significantly attenuated inflammation in animals. These findings indicate that the ethosome preparation represents a promising approach for enhancing anti-inflammatory efficacy.

01 Mar 2026·Biochemistry and Biophysics Reports

Betanin ameliorates dextran sulfate sodium-induced colitis in mice by modulating tight junction protein expression

Article

Author: Ozaki, Noriyuki ; Okuda, Hiroaki ; Ishikawa, Tatsuya ; Kwankaew, Nichakarn ; Hori, Kiyomi

The incidence of inflammatory bowel disease (IBD), a chronic inflammatory condition of the gastrointestinal tract characterized by a progressive and unpredictable disease course, has been increasing in many parts of the world. Inflammation and tight junction disruption in the mucosa play key roles in IBD pathogenesis, highlighting inflammation inhibition as a promising therapeutic strategy. Betanin, a red beetroot pigment, possesses potent anti-inflammatory and antioxidant properties, suggesting its potential as a treatment to ameliorate for IBD symptoms. In this study, we evaluated whether betanin alleviates symptoms in a mouse model of colitis and explored its underlying mechanisms. Betanin administration via intraperitoneal or oral injection reduced body weight loss and rectal bleeding and alleviated histological damage in the distal colon of dextran sulfate sodium (DSS)-induced IBD mice model. Moreover, intraperitoneal injection of betanin inhibited the activation of macrophages and enteric glial cells in DSS-induced colitis mice model. Furthermore, it attenuated DSS-induced downregulation of the tight junction proteins occludin and claudin-1. These findings suggest that betanin may improve IBD symptoms by suppressing inflammation and preserving tight junction function in colitis mice model.

01 Mar 2026·JOURNAL OF MAGNETIC RESONANCE IMAGING

Betanin‐Based Contrast Agents for MRI : A Preliminary Experimental Study

Article

Author: Esen, Alperen C. ; Özsunar, Yelda ; Tataroğlu, Canten ; Bilgen, Mehmet ; Aktaş, Serdar ; Kurt, Berrak ; Kayhan, Handan

ABSTRACT:

Background:

Gadolinium‐based contrast agents (GBCAs) are used in MRI, yet concerns about gadolinium ion release, tissue retention, rare adverse events, and environmental persistence have encouraged the search for alternatives. Prior work on plant‐based extracts has been largely confined to gastrointestinal luminal imaging, with limited exploration in extraluminal organs as contrast agents.

Purpose:

To preclinically investigate the potentials of Betanin and beetroot‐derived Betanin‐based contrast agents (BBCA) in vitro and in vivo via oral, intravenous, and intraperitoneal administration, and to compare them with gadobutrol (a GBCA).

Study Type:

Prospective preclinical experimental study.

Subjects:

In vitro studies on human and mouse fibroblast cell lines, and in vivo tests involving male Wistar albino rats ( n = 15) and male New Zealand albino rabbits ( n = 2).

Field Strength/Sequence:

3 T, spin echo, and gradient echo sequences.

Assessment:

Betanin and BBCA compositions were characterized by mass spectrometry. Safety was assessed by in silico modeling, cytotoxicity, flow cytometry, histology, and blood biochemistry tests. Images of phantom solutions were used to characterize the paramagnetic features via MR relaxation times and relaxivities. In vivo contrast behavior in organs was evaluated following oral, intraperitoneal, and intravenous administrations.

Statistical Tests:

The quantitative data were analyzed with Microsoft Excel and GraphPad Prism 9.0; p value < 0.05 was significant.

Results:

Betanin had greater molecular binding efficiency and therapeutic capacity. BBCA was less cytotoxic than gadobutrol. Some elements in BBCA were present in larger amounts than Betanin. T1 and T2 decreased with an increase in BBCA concentration, and r1 and r2 were estimated as 0.0014 and 0.0224 mmol −1 s −1 , respectively. Both agents demonstrated contrast enhancements not only in the gastrointestinal lumen but also in the parenchymal organ, as well as in the vascular structure, with lower toxicity and antioxidative benefits. In particular, the enhancement in the liver was noteworthy.

Data Conclusion:

Betanin and BBCA may be considered as viable options for contrast‐enhanced abdominal MRI.

100 Deals associated with Betanin

Login to view more data